Sodium-glucose cotransporter 2 (SGLT2) inhibitors, dapagliflozin, and empagliflozin, first developed as glucose-lowering agents for the treatment of Type 2 diabetes, have been demonstrated to improve prognosis in patients with heart failure and reduced ejection fraction (HFrEF) regardless of the presence of diabetes. Since these drugs have only recently been included among the four pillars of HFrEF treatment, cardiologists are still unfamiliar with their use in this setting. This article provides an up-to-date practical guide for the initiation and monitoring of patients treated with SGLT2 inhibitors.
ANMCO statement on the use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure: A practical guide for a streamlined implementation / Di Fusco, S. A.; Gronda, E.; Mocini, E.; Luca, F.; Bisceglia, I.; De Luca, L.; Caldarola, P.; Cipriani, M.; Corda, M.; De Nardo, A.; Francese, G. M.; Napoletano, C.; Navazio, A.; Riccio, C.; Roncon, L.; Tizzani, E.; Nardi, F.; Urbinati, S.; Valente, S.; Gulizia, M. M.; Gabrielli, D.; Oliva, F.; Imperoli, G.; Colivicchi, F.. - In: EUROPEAN HEART JOURNAL SUPPLEMENTS. - ISSN 1554-2815. - 24:(2022), pp. C272-C277. [10.1093/eurheartj/suac017]
ANMCO statement on the use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure: A practical guide for a streamlined implementation
Mocini E.;
2022
Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, dapagliflozin, and empagliflozin, first developed as glucose-lowering agents for the treatment of Type 2 diabetes, have been demonstrated to improve prognosis in patients with heart failure and reduced ejection fraction (HFrEF) regardless of the presence of diabetes. Since these drugs have only recently been included among the four pillars of HFrEF treatment, cardiologists are still unfamiliar with their use in this setting. This article provides an up-to-date practical guide for the initiation and monitoring of patients treated with SGLT2 inhibitors.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
